Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema

Core Insights - Clearside Biomedical, Inc. has entered a commercial collaboration agreement with Arctic Vision and Santen Pharmaceutical Co., Ltd. for the commercialization of ARVN001 (XIPERE®) in China, targeting uveitic macular edema and other ophthalmic indications [1][2] - The partnership is expected to enhance the validation of Clearside's Suprachoroidal Space (SCS®) delivery platform, which is gaining traction among global pharmaceutical companies [2][3] - Arctic Vision has reported positive Phase 3 trial results for ARVN001 in China and is pursuing regulatory approvals in multiple Asia-Pacific countries [3] Company Overview - Clearside Biomedical specializes in innovative drug delivery systems for ocular diseases, utilizing its proprietary SCS Microinjector® to administer therapies directly to the back of the eye [5][9] - The company’s lead product, XIPERE®, is a corticosteroid suspension approved in the U.S. for treating macular edema associated with uveitis, and is commercially available through Bausch + Lomb [6][9] - Clearside is also developing a pipeline of small molecule candidates for ocular conditions, with its lead program, CLS-AX, for wet age-related macular degeneration, recently completing a Phase 2b trial [9] Market Context - Uveitis affects approximately 350,000 patients in the U.S. and over one million globally, with about one-third developing uveitic macular edema, a significant cause of vision loss [8] - The uveitis market is projected to grow to nearly $550 million in the U.S. and over$1 billion globally by 2024 [8]